These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 25921689)

  • 21. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.
    Cressey TR; Siriprakaisil O; Kubiak RW; Klinbuayaem V; Sukrakanchana PO; Quame-Amaglo J; Okochi H; Tawon Y; Cressey R; Baeten JM; Gandhi M; Drain PK
    Int J Infect Dis; 2020 Aug; 97():365-370. PubMed ID: 32553717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
    Markowitz M; Zolopa A; Squires K; Ruane P; Coakley D; Kearney B; Zhong L; Wulfsohn M; Miller MD; Lee WA
    J Antimicrob Chemother; 2014 May; 69(5):1362-9. PubMed ID: 24508897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
    Baheti G; King JR; Acosta EP; Fletcher CV
    AIDS; 2013 Jan; 27(2):221-5. PubMed ID: 23032419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
    van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
    Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients.
    Du X; Kou H; Fu Q; Li Y; Zhu Z; Li T
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):783-788. PubMed ID: 28480762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
    Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
    Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
    Feng HP; Guo Z; Caro L; Talaty JE; Mangin E; Panebianco D; Fandozzi C; Zhu Y; Marshall W; Huang X; Hanley WD; Jumes P; Valesky R; Martinho M; Butterton JR; Iwamoto M; Yeh WW
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):962-970. PubMed ID: 31173674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
    Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.
    Lamorde M; Walimbwa S; Byakika-Kibwika P; Katwere M; Mukisa L; Sempa JB; Else L; Back DJ; Khoo SH; Merry C
    J Antimicrob Chemother; 2015 May; 70(5):1482-6. PubMed ID: 25652748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
    Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).
    Robinson JA; Marzinke MA; Fuchs EJ; Bakshi RP; Spiegel HML; Coleman JS; Rohan LC; Hendrix CW
    J Acquir Immune Defic Syndr; 2018 Feb; 77(2):175-182. PubMed ID: 29135651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.
    Seifert SM; Chen X; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Clayton C; Austin G; Palmer BE; Zheng JH; Klein B; Kerr BJ; Guida LA; Rower C; Rower JE; Kiser JJ; Bushman LR; MaWhinney S; Anderson PL
    AIDS Res Hum Retroviruses; 2016; 32(10-11):981-991. PubMed ID: 27526873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
    Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
    la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
    Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.
    Lê MP; Landman R; Koulla-Shiro S; Charpentier C; Sow PS; Diallo MB; Ngom Gueye NF; Ngolle M; Le Moing V; Eymard-Duvernay S; Benalycherif A; Delaporte E; Girard PM; Peytavin G;
    J Antimicrob Chemother; 2015 May; 70(5):1517-21. PubMed ID: 25583749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
    Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
    Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
    Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
    BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.